Ibl Healthcare Limited · PSX:IBLHL
Ibl Healthcare — Investor Presentation (November 2025)
18 slides from Ibl Healthcare's investor presentation, Nov 20, 2025
Slide 1: IBL HealthCare Limited Corporate Briefing Session
IBL HealthCare Limited Corporate Briefing Session November 20, 2025
Slide 2: Session outline
Session outline - Company overview - Financial highlights - Future outlook - Question & answers
Slide 3: Company overview
HEALT! RE ‘SEARI Company overview
Slide 4: Company overview
Company overview • Incorporated as Private Limited company in July 1997. • In November 2008, Company’s shares were listed on Pakistan Stock Exchange. • IBL HealthCare Limited (IBLHC) is a subsidiary of The Searle Company Limited. • IBLHC is engaged in marketing & distribution of nutrition, medical d
Slide 5: Purpose and values
Purpose and values Purpose statement Values Elevating life by advancing health and well-being for generations to come.
Slide 6: Business partners
Business partners ISL HEALTHCARE SEARLE Y, ~. ® a Health WHOLE Meadjohnsom® s* Nestle Sen: Wieta <> Vinamilk ii =] a WEGOHS <<. “Ena EST 1976 [*] TOP QUALITY, TOP EFFICIENCY samme 05 admd 2OE> Une yIngwues”
Slide 7: Product portfolio - Nutrition
Product portfolio - Nutrition
Slide 8: Product portfolio - Consumer
Product portfolio - Consumer
Slide 9: Product portfolio – Medical devices
Product portfolio – Medical devices
Slide 10: Financial highlights
HEALTHCARE SEARLE Financial highlights
Slide 11: Financial highlights – FY 2025
Financial highlights – FY 2025 Operating Net revenue Gross profit Net profit profit 20% 52% 148% 2658% PKR 4.3 b PKR 1.4 b (33%) PKR 437 m (10%) PKR 208 m (5%)
Slide 12: Financial snapshot
Financial snapshot FY 2022 FY 2023 FY 2024 FY 2025 Revenue 3,651,125 4,027,874 3,603,359 4,322,471 Cost of sales 2,394,888 2,687,427 2,651,543 2,875,495 Gross profit 1,256,237 1,340,447 951,816 1,446,976 Operating expenses (745,651) (815,875) (775,722) (1,009,673) Operating profit 510,586 524,572 17
Slide 13: Revenue and gross profit trends
Revenue and gross profit trends 1,400 Millions 1,200 1,000 800 600 400 200 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 (200) FY22 FY23 FY24 FY25 (400) Gross profit Revenue
Slide 14: Future outlook
HEALT! RE ‘SEARI Future outlook
Slide 15: Industry landscaping: emerging and priority opportunities
Industry landscaping Emerging opportunities Priority opportunities Women’s Health Stevia-based sweeteners Competitive advantage Holistic adult nutrition Cough, Cold & Flu remedies Divest Build Capability / Partner Pharmaceutical VFM Infant Nutrition Ophthalmology Expansion / localization of Medical
Slide 16: Mid- to Long-term Sourcing and Supply Chain Strategy
Mid- to Long-term Sourcing and Supply Chain Strategy Localization Export
Slide 17: Q&A
ISL HEALTHCARE A SEARLE Subsidiar Q&A
Slide 18: Thank you!
HEALT! RE \ SEAR Thank you!
IBL HealthCare — Investor Presentation (November 2025) on 6ix